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Abstract

Key Points

IMPORTANCE Black men have a 2-fold increased risk of dying from prostate cancer compared with
White men. However, race-specific differences in response to initial treatment remain unknown.
OBJECTIVE To compare overall and treatment-specific outcomes of Black and White men with

Question Is there a difference in
outcomes between Black and White
men with localized prostate cancer
receiving definitive radiotherapy (RT)?
Findings In this meta-analysis that

localized prostate cancer receiving definitive radiotherapy (RT).

included 8814 patients treated with

DATA SOURCES A systematic search was performed of relevant published randomized clinical trials

definitive RT enrolled in 7 randomized

conducted by the NRG Oncology/Radiation Therapy Oncology Group between January 1, 1990, and

clinical trials, Black men were

December 31, 2010. This meta-analysis was performed from July 1, 2019, to July 1, 2021.

significantly less likely to experience a
biochemical recurrence, distant

STUDY SELECTION Randomized clinical trials of definitive RT for patients with localized prostate

metastasis, and prostate cancer–specific

cancer comprising a substantial number of Black men (self-identified race) enrolled that reported on

mortality event than White men.

treatment-specific and overall outcomes.

Meaning The findings of this metaanalysis noted that Black men enrolled

DATA EXTRACTION AND SYNTHESIS Individual patient data were obtained from 7 NRG Oncology/
Radiation Therapy Oncology Group randomized clinical trials evaluating definitive RT with or without
short- or long-term androgen deprivation therapy. Unadjusted Fine-Gray competing risk models,
with death as a competing risk, were developed to evaluate the cumulative incidences of end points.
Cox proportional hazards models were used to evaluate differences in all-cause mortality and the
composite outcome of distant metastasis (DM) or death. The Preferred Reporting Items for

in randomized clinical trials presented
with more aggressive disease features
but had better treatment and diseasespecific outcomes with RT-based
therapy compared with White men,
suggesting other important factors

Systematic Reviews and Meta-Analyses (PRISMA) guideline was followed.

associated with outcome, such as access
to care, as sources of disparity.

MAIN OUTCOMES AND MEASURES Subdistribution hazard ratios (sHRs) of biochemical recurrence
(BCR), DM, and prostate cancer-specific mortality (PCSM).
RESULTS A total of 8814 patients (1630 [18.5%] Black and 7184 [81.5%] White) were included;
mean (SD) age was 69.1 (6.8) years. Median follow-up was 10.6 (IQR, 8.0-17.8) years for surviving
patients. At enrollment, Black men were more likely to have high-risk disease features. However,

+ Invited Commentary
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Author affiliations and article information are
listed at the end of this article.

even without adjustment, Black men were less likely to experience BCR (sHR, 0.88; 95% CI,
0.58-0.91), DM (sHR, 0.72; 95% CI, 0.58-0.91), or PCSM (sHR, 0.72; 95% CI, 0.54-0.97). No
significant differences in all-cause mortality were identified (HR, 0.99; 95% CI, 0.92-1.07). Upon
adjustment, Black race remained significantly associated with improved BCR (adjusted sHR, 0.79;
95% CI, 0.72-0.88; P < .001), DM (adjusted sHR, 0.69; 95% CI, 0.55-0.87; P = .002), and PCSM
(adjusted sHR, 0.68; 95% CI, 0.50-0.93; P = .01).
(continued)
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Abstract (continued)

CONCLUSIONS AND RELEVANCE The findings of this meta-analysis suggest that Black men
enrolled in randomized clinical trials present with more aggressive disease but have better BCR, DM,
and PCSM with definitive RT compared with White men, suggesting that other determinants of
outcome, such as access to care, are important factors of achieving racial equity.
JAMA Network Open. 2021;4(12):e2139769. doi:10.1001/jamanetworkopen.2021.39769

Introduction
Black men are more likely to be diagnosed with prostate cancer and are more likely to die from the
disease compared with White men.1 Evidence suggests that a large proportion of these differences
may be attributable to socioeconomic factors and/or disparities in guideline-concordant care.2-4 Data
also suggest that biological differences may exist that could help explain in part the observed
population-based disparities in prostate cancer outcomes.5-7
In the context of metastatic disease, data suggest improved efficacy of abiraterone,8
docetaxel,9 and sipuleucel-T 10 in Black compared with non-Black men. Additional studies suggest
prostate cancer–specific mortality (PCSM) outcomes are similar for patients receiving definitive
therapy for localized disease, provided equal access to care, and receiving standardized treatments.2
However, the end point of PCSM, albeit important, is the culmination of often many years of multiple
salvage therapies and does not intrinsically capture the initial responsiveness to primary therapy. To
our knowledge, no large-scale study has been conducted to examine race and the early metrics of
response to treatment, including biochemical recurrence (BCR) or the development of distant
metastasis (DM) in men with localized prostate cancer; thus, it is unknown whether there is an initial
differential response to treatment by race. Because most patients with prostate cancer present with
localized disease, understanding potential differences in the initial response to therapy is necessary
to identify potential factors and/or mitigators of disparities in prostate cancer care.
To elucidate associations between race and both early (ie, BCR and DM) and late (ie, PCSM and
all-cause mortality [ACM]) outcomes of treatment efficacy among men with localized prostate
cancer, we performed the largest individual patient data meta-analysis to date of men with localized
prostate cancer enrolled in 7 randomized trials using definitive RT with varying schedules of
androgen deprivation therapy (ADT).

Methods
Patients and Trial Inclusion
We performed a systematic literature search to identify relevant randomized clinical trials run by the
NRG Oncology/Radiation Therapy Oncology Group (RTOG) from January 1, 1990, to December 31,
2010, which has historically enrolled a substantial number of Black men in its trials.11,12 This
systematic review and meta-analysis was performed from July 1, 2019, to July 1, 2021. Seven trials for
which individual patient-level data were available were identified (eFigure 1 and eTable 1 in the
Supplement). Data sharing applications were submitted to NRG Oncology to obtain individual
patient-level data for patients enrolled in RTOG protocols 9202,13 9408,14 9413,15 9902,16 9910,17
0126,18 and 0415.19 Specific information on inclusion criteria and treatment details is presented in
eTable 1 in the Supplement. Patients who had node-positive disease (clinically or via pathologic
sampling) were excluded. Data were extracted for men who self-identified as Black or White race and
reviewed by 2 of us (T.R. and A.U.K.). The arms of each trial were merged into 1 of 4 larger groups (ie,
treatment strategies): RT alone, RT with short-term ADT, RT with long-term ADT, and high-dose RT
(eTable 2 in the Supplement). RT doses higher than 74 Gy were considered high dose (presuming an
α/β ratio of 3.0 to convert hypofractionated schedules). The duration of short-term ADT was 4
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months (except for RTOG 9910, in which the arm with 9 months of ADT was included as it was not
oncologically different from the 4-month ADT arm) while that of long-term ADT was 24 to 28
months. The study was approved by the University of California Los Angeles Institutional Review
Board. This study followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses
(PRISMA) reporting guideline.

Study End Points
The primary outcomes of interest for the current analysis were BCR, DM, and PCSM. For BCR, in all
trials (except RTOG 9902), the Phoenix definition (increase of prostate-specific antigen [PSA] level
by ⱖ2 ng/mL [1:1 conversion to micrograms per liter] above the nadir) was used. For RTOG 9902, the
ASTRO definition (3 consecutive PSA increases after a nadir) was used. All-cause mortality was
considered a secondary end point because data regarding comorbidity status were not available, and
comorbidity status has been shown to limit estimation of ACM, both for prostate cancer in general20
and when investigating associations between race and outcome specifically.2 A composite outcome,
defined as death or DM, was also explored as the inverse of metastasis-free survival—a validated
surrogate marker for overall survival in patients receiving definitive RT for prostate cancer.21 Time to
event was defined as per each study (generally, from time of randomization to the end point in
question).

Statistical Analysis
Differences in age and initial PSA level between races were evaluated with a Wilcoxon rank sum test,
and differences in categorical variables (including PSA level with cut points, performance status,
National Comprehensive Cancer Network (NCCN) risk group, Gleason score [higher scores indicate
greater risk], and cT category) were compared using the Fisher exact test. Cumulative incidences of
BCR, DM, PCSM, and other-cause mortality for each trial were estimated with a competing risk
method. Cumulative incidences of death or DM and of ACM were estimated for each trial with
Kaplan-Meier methods. Each trial-level estimate was then pooled to provide an estimate for the
entire cohort using a meta-analysis approach with random effects. We also developed cumulative
incidence and survival curves that were weighted for the inverse probability of being enrolled in a
given trial. Weights were determined based on a multinomial logistic regression with trial as the
outcome and age, initial PSA level, Gleason score, T category, and treatment strategy as independent
covariates. To evaluate associations between race and BCR, DM, and PCSM, a network metaanalysis was performed. First, the trial-specific subdistribution hazard ratios (sHRs) for the
associations between race and BCR, DM, and PCSM in the presence of competing risks were
estimated using the multivariable Fine-Gray method with age at treatment, ln(initial PSA level),
treatment strategy, T category, and Gleason score as independent covariates. Death from any cause
was considered a competing risk for BCR and DM, and other-cause mortality was considered a
competing risk for PCSM. Other-cause mortality was modeled similarly, with PCSM as the competing
risk event. Next, trial-specific estimates were combined using traditional meta-analysis methods with
random effects to obtain a pooled overall estimate.
The same approach was used to conduct a 2-step random effect meta-analysis to estimate the
unadjusted association between race and each end point within predefined subgroups. The
categories were defined as age (ⱕ65 vs >65 years), NCCN risk grouping,22 PSA level (<10, 10-20, >20
ng/mL), Gleason score (6, 7, 8-10), T category (T1-2 vs T3-4), and treatment strategy (RT alone, RT
with short-term ADT, RT with long-term ADT, and high-dose RT alone). To adjust for multiple
comparisons when estimating within categories (HRs and sHRs), we report q values that were
adjusted for false discovery rates. P values were 2-tailed, and statistical significance was set at
P = .05. All statistical analyses were conducted using SAS, version 9.4 (SAS Institute Inc) and
Packages metafor and netmeta (Network Meta-Analysis using Frequentist Methods)23 in R,
version 3.3.1.24
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Results
Patient and Trial Characteristics
Overall, 8814 patients (Black, 1630 [18.5%]; White, 7184 [81.5%]) were identified. The mean (SD) age
overall was 69.1 (6.8) years (Black, 67.1 [7.3] years; White, 69.6 [6.6] years). The cohort comprised
primarily patients with NCCN risk levels of low (1748 [19.8%]) and intermediate (4263 [48.4%]); the
remaining patients had high-risk disease (2803 [31.8%]). Risk groups were defined by the NCCN22
as low risk (cT1-T2a, Gleason score ⱕ6, and PSA level <10 ng/mL), intermediate risk (cT2b-T2c,
Gleason score 7, or PSA level 10-20 ng/mL, and high risk (cT3a or Gleason score 8-10 or PSA level >20
ng/mL). Patient characteristics are presented in Table 1. Median follow-up was 10.6 (IQR, 8.0-17.8)
years for living patients using the inverse Kaplan-Meier method. On average, 19.5% of patients in any
of the 7 evaluated studies were of Black race, with RTOG 0126 having the lowest percentage of Black
patients (188 of 1440 [13.1%]), and RTOG 9902 having the highest (102 of 367 [27.8%]).
Overall, Black men presented at a significantly younger age (median [IQR], 68 [62-73] vs 71
[66-74] years; P < .001). They were also significantly more likely to present with high-risk disease

Table 1. Baseline Clinical and Demographic Characteristics
No. (%)
Variable

P valuea

Black race (n = 1630)

White race (n = 7184)

Mean (SD)

67.1 (7.3)

69.6 (6.6)

<.001

Median (IQR)

68 (62-73)

71 (66-74)

<.001

Low

325 (19.9)

1423 (19.8)

Intermediate

683 (41.9)

3580 (49.8)

High

622 (38.2)

2181 (30.4)

Mean (SD)

16.2 (16.4)

12 (12.1)

<.001

Median (IQR)

10.3 (6.2-19.1)

8.4 (5.7-13.2)

<.001

<10

704/1527 (46.1)

3631/6327 (57.4)

10-20

490/1527 (32.1)

2005/6327 (31.7)

>20

333/1527 (21.8)

691/6327 (10.9)

6

733/1608 (45.6)

2975/7086 (42.0)

7

613/1608 (38.1)

3114/7086 (43.9)

8

173/1608 (10.8)

599/7086 (8.5)

9

80/1608 (5.0)

345/7086 (4.9)

10

9/1608 (0.6)

53/7086 (0.7)

1

772/1528 (50.5)

2857/6919 (41.3)

2

497/1528 (32.5)

2766/6919 (40.0)

3

206/1528 (13.5)

968/6919 (14.0)

4

53/1528 (3.5)

328/6919 (4.7)

RTOG 9202

186 (11.4)

1228 (17.1)

RTOG 9408

394 (24.2)

1497 (20.8)

Age, y

NCCN risk

<.001

PSA level, ng/mLb

PSA level, ng/mLb

<.001

Gleason scorec

<.001

T category

<.001

Abbreviations: NCCN, National Comprehensive Cancer
Network; PSA, prostate-specific antigen.

Trial

RTOG 9413

322 (19.8)

881 (12.3)

RTOG 9902

102 (6.3)

265 (3.7)

RTOG 9910

246 (15.1)

1190 (16.6)

RTOG 0126

188 (11.5)

1252 (17.4)

RTOG 0415

192 (11.8)

871 (12.1)

SI conversion of PSA levels to micrograms per liter is 1:1.
a

P value was calculated excluding patients in the
unknown category for each variable.

b

Individual PSA values not known for RTOG 9202,
because only PSA levels dichotomized to less than or
equal to 30 vs greater than 30 ng/mL were provided.

c

Higher scores indicate greater risk.

<.001
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(622 [38.2%] vs 2181 [30.4%]; P < .001), higher PSA levels (median [IQR], 10.3 [6.2-19.1] vs 8.4 [5.713.2] ng/mL; P < .001), and Gleason scores of 8 to 10 (262 of 1608 [16.3%] vs 997 of 7086 [14.1%];
P = .03). However, there was no difference in the proportion of patients with cT3-4 disease (259
[17.0%] vs 1296 [18.7%]; P = .10), although Black men were more likely to have cT1 disease (772
[50.5%] vs 2857 [41.3%]; P < .001).

Cumulative Incidences of End Points
Individual trial crude event rates within the Black and White subgroups are reported in eTable 3 in the
Supplement. Compared with White men, Black men had lower absolute unadjusted 10-year
cumulative incidence rates of BCR (40.5% vs 44.6%; P = .006), DM (8.4% vs 11.6%; P = .005), and
PCSM (4.5% vs 6.4%; P = .03). Ten-year rates of ACM and death or DM were similar (ACM: 39.8% vs
41.2%; log-rank test, P = .43; death or DM: 41.5% vs 43.6%; log-rank test, P = .40). Other-cause
mortality was also similar (10-year rates of 37.2% vs 36.6%; P = .50). Proportions of death
attributable to PCSM vs other-cause mortality overall and based on age and NCCN risk group are
shown in eFigure 2 in the Supplement, with additional information on breakdown by other
prespecified subgroups shown in eFigure 3 in the Supplement. A lower percentage of mortality
events were due to PCSM rather than other-cause mortality overall (50 of 773 [6.5%] vs 368 of 3617
[10.2%]) and among men younger than 65 years (17 of 225 [7.6%] vs 93 of 624 [14.9%]) and aged
65 years or older (33 of 548 [6.0%] vs 275 of 2993 [9.2%]) as well as men with high-risk disease (24
of 374 [6.4%] vs 188 of 1480 [12.7%]). To account for ecological biases and include time to event
considerations, we also developed cumulative incidence and survival curves that were weighted for
the inverse probability of being enrolled in a given trial (Figure 1).

Competing Risk and Cox Proportional Hazards Models
The forest plots depicting the results of our 2-step unadjusted meta-analysis evaluating BCR, DM,
PCSM, and ACM are shown in Figure 2 and Figure 3. Overall, Black race was associated with a lower
risk of BCR (sHR, 0.88; 95% CI, 0.80-0.96; P = .006), DM (sHR, 0.72; 95% CI, 0.58-0.91; P = .005),
and PCSM (sHR, 0.72; 95% CI, 0.54-0.97; P = .03). There was no significant difference in time to ACM
(HR, 0.99; 95% CI, 0.92-1.07; P = .87). Similarly, there was no significant difference in time to othercause mortality (sHR, 1.03; 95% CI, 0.95-1.12; P = .50), and DM or death (HR, 1.00; 95% CI, 0.92-1.08;
P = .91) (eFigure 4 in the Supplement). When examined within predefined strata, Black race was
similarly associated with a lower risk of BCR, DM, and PCSM among men aged 65 years or younger.
Black race was also associated with a lower risk of BCR and DM among men with high-risk disease,
PSA level greater than 20 ng/mL, and men receiving RT with short-term ADT. We also evaluated the
association between race and BCR, DM, and PCSM with a network meta-analysis while adjusting for
age, initial PSA level, T category, Gleason score, and treatment strategy (Table 2). Black race was
significantly associated with improved BCR (adjusted sHR, 0.79; 95% CI, 0.72-0.88; P < .001), DM
(adjusted sHR, 0.69; 95% CI, 0.55-0.87; P = .002), and PCSM (adjusted sHR, 0.68; 95% CI, 0.5-0.93;
P = .01).

Discussion
In this individual patient data meta-analysis of 7 randomized clinical trials, Black men were
significantly more likely to have high-risk disease and a younger age at the time of treatment, yet had
lower BCR, DM, and PCSM rates compared with White men, even without adjustment. In an adjusted
network meta-analysis that accounted for age, initial PSA level, T category, Gleason score, and
treatment strategy, race remained significantly associated with improved BCR, DM, and PCSM
outcomes. No significant differences were found with respect to ACM or the composite outcome DM
or death, and most mortality events in either Black or White men were other-cause mortality events.
The fact that Black men had improved early and late disease outcomes compared with White men is a
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novel and unexpected result, suggesting that Black men may have an improved response to their
initial treatment.
A 2019 meta-analysis focusing on men with advanced disease reported a significant increase in
overall survival in Black vs White men with metastatic castrate-resistant prostate cancer treated with
docetaxel in phase 3 clinical trials.9 Other data suggest a similar increased efficacy of abiraterone8
and sipeulecel-T.10 An earlier report, predominantly assessing men with prostate cancer diagnosed

Figure 1. Cumulative Incidence and Survival Curves Weighted for the Inverse Probability of Trial Enrollment
A Biochemical recurrence

B

Distant metastasis
1.00

Cumulative incidence

Cumulative incidence

1.00

0.75
White
0.50
Black
0.25

0.75

0.50

0.25
White
Black

0

0
0

5

10

15

20

0

5

Years after treatment
No. at risk (No. censored)
Black
671 (0)
354 (90)
White
4383 (0)
2270 (377)
C

123 (204)
850 (1108)

10

15

20

83 (354)
777 (2482)

4 (414)
157 (3010)

Years after treatment

50 (250)
358 (1397)

2 (287)
81 (1622)

No. at risk (No. censored)
Black
671 (0)
480 (98)
White
4383 (0)
3481 (481)

224 (254)
1517 (1938)

D Distant metastasis-free survival

Prostate cancer–specific mortality and other-cause mortality
1.00

1.00

Black

Other-cause mortality

White

0.50

0.25
Cancer-specific mortality

Cumulative incidence

Cumulative incidence

White
0.75

0.75
Black
0.50
+

++

White
Black

0
0

5

10

0

15

0

Years after treatment
No. at risk (No. censored)
671 (0)
Black
4383 (0)
White
E

512 (20)
3581 (98)

+

0.25

5

10

15

Years after treatment

244 (88)
1648 (509)

90 (226)
839 (1552)

No. at risk (No. censored)
671 (0)
Black
4383 (0)
White

480 (20)
3481 (95)

224 (83)
1517 (491)

83 (213)
777 (1449)

Overall survival

Cumulative incidence

1.00

0.75
Black
0.50
White
0.25

0
0

5

10

15

Years after treatment
No. at risk (No. censored)
Black
671 (0)
4383 (0)
White

512 (20)
3581 (98)

244 (88)
1648 (509)

90 (226)
839 (1552)

Cumulative incidence curves for biochemical recurrence (A), distant metastasis (B),
prostate cancer–specific mortality and other-cause mortality (C), distant metastasis-free
survival (D), and overall survival (E). All curves were weighted for the inverse probability

of enrollment on a given trial. Weights were determined based on a multinomial logistic
regression with trial as the outcome and age, prostate-specific antigen level, Gleason
score, T category, and treatment strategy as independent covariates.
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between 1980 and 1990, found that Black men presenting with metastatic prostate cancer had
improved survival compared with White men.25 To our knowledge, whether a parallel association
between Black race and improved early disease outcomes (ie, BCR and DM) might be present among
men presenting with localized disease—comprising most men with newly diagnosed prostate
cancer—has not been extensively studied. These earlier end points are important given the
prolonged natural history of localized prostate cancer both in general26,27 and after BCR,28,29 as well
as the availability of effective treatments for patients with DM.30 This study provides, to our
knowledge, the most comprehensive analysis of the association between race and multiple end
points in patients with localized prostate cancer.
The results should be contextualized with other studies that have focused on potential
associations between race and outcomes in men with localized prostate cancer. A recent metaanalysis, which included 4 of the 7 randomized clinical trials we used, reported that Black race was
not associated with worse PCSM outcome.2 In that study, analyses were adjusted to account for
imbalances in age and risk features (including risk group itself) to underscore the disparities in access
to care and uncontrolled treatment selection on PCSM outcomes. McKay et al31 recently reported
the outcomes in patients with nonmetastatic prostate cancer treated with definitive radiotherapy at
152 centers within the Veterans Health Administration and found that Black race was associated with
a decreased risk of PCSM and ACM. In the present report, we broadened the analysis to a larger
cohort of men (including 44% more Black men) and specifically interrogated not only PCSM, but
earlier disease outcomes, such as BCR and DM. In our main 2-step meta-analysis approach, we did
not perform any adjustments, although differences in important prognostic variables, such as NCCN

Figure 2. Estimates of Association Between Race and Biochemical Recurrence and Distant Metastasis
A Biochemical recurrence

Variable

Favors
lower risk

sHR (95% CI)

B

Favors
higher risk

q Value

Distant metastasis

Variable

Favors
lower risk

sHR (95% CI)

Favors
higher risk q Value

T category

T category
T1-T2

0.91 (0.81-1.01)

.204

T1-T2

0.77 (0.60-0.98)

.118

T3-T4

0.80 (0.57-1.11)

.304

T3-T4

0.75 (0.55-1.02)

.144

Age, y

Age, y
≤65

0.81 (0.69-0.94)

.050

≤65

0.60 (0.45-0.80)

.009

>65

0.88 (0.78-0.99)

.112

>65

0.76 (0.55-1.05)

.159

NCCN risk stratification

NCCN risk stratification
Low

0.85 (0.56-1.30)

.553

Low

0.63 (0.25-1.60)

.370

Intermediate

0.91 (0.77-1.07)

.365

Intermediate

0.80 (0.57-1.13)

High

0.86 (0.75-0.98)

.092

High

0.70 (0.53-0.92)

.311
.042

6

0.90 (0.74-1.09)

.386

6

0.69 (0.47-1.01)

.144

7

0.89 (0.77-1.03)

.254

7

0.84 (0.63-1.12)

.321

8-10

0.85 (0.69-1.05)

.254

8-10

0.72 (0.50-1.04)

.144

Gleason score

Gleason score

PSA

PSA
<10

0.94 (0.75-1.16)

.624

<10

0.84 (0.56-1.26)

.415

10-20

0.77 (0.64-0.93)

.050

10-20

0.77 (0.46-1.29)

.370

>20

0.85 (0.72-0.99)

.112

>20

0.68 (0.51-0.90)

.041

RT strategy

RT strategy
RT alone

0.89 (0.74-1.09)

.365

RT alone

0.86 (0.53-1.40)

.554

High-dose RT

0.97 (0.67-1.42)

.885

High-dose RT

1.63 (0.67-3.99)

.370

RT + STADT

0.85 (0.75-0.97)

.078

RT + STADT

0.72 (0.57-0.91)

.041

RT + LTADT

0.98 (0.78-1.22)

.883

RT + LTADT

0.54 (0.28-1.04)

.144

Race

Race
Black vs White men

0.88 (0.80-0.96)

.006
0.50

0.75

1

Black vs White men

2

.005
0.25

sHR (95% CI)

Associations between race and biochemical recurrence (A) and distant metastasis (B)
were modeled with the unadjusted Fine-Gray method yielding subdistribution hazard
ratio (sHR) method. Trial-specific estimates were generated and then combined with a
2-step meta-analysis method with random effects to obtain overall estimates. LTADT

0.72 (0.58-0.91)
0.50 0.75 1

2.5

sHR (95% CI)

indicates long-term androgen deprivation therapy; NCCN, National Comprehensive
Cancer Network; PSA, prostate-specific antigen; RT, radiotherapy; sHR, subdistribution
hazard ratio; and STADT, short-term androgen deprivation therapy. SI conversion of PSA
levels to micrograms per liter is 1:1.
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risk stratum and Gleason score, were present. We did not adjust the analyses because other
important variables, such as percentage of positive biopsy cores, primary Gleason score, and
performance status, were not readily available, we believed it was most appropriate to evaluate

Figure 3. Estimates of Association Between Race and Prostate Cancer–Specific Mortality (PCSM) and All-Cause Mortality (ACM)
A PSCM

Variable

Favors
lower risk

sHR (95% CI)

Favors
higher risk

B

q Value

ACM

Variable

Favors
lower risk

sHR (95% CI)

Favors
higher risk

q Value

T category

T category
T1-T2

0.74 (0.51-1.07)

.249

T1-T2

1.03 (0.94-1.13)

.989

T3-T4

0.69 (0.42-1.12)

.249

T3-T4

0.93 (0.79-1.09)

.989

Age, y

Age, y
≤65

0.59 (0.35-1.00)

.249

≤65

1.09 (0.94-1.28)

.989

>65

0.77 (0.54-1.11)

.249

>65

1.05 (0.96-1.15)

.989

NCCN risk stratification

NCCN risk stratification
Low

0.36 (0.08-1.54)

.249

Low

0.98 (0.74-1.30)

.989

Intermediate

0.78 (0.50-1.19)

.300

Intermediate

1.02 (0.90-1.15)

High

0.71 (0.46-1.09)

.249

High

0.96 (0.86-1.08)

.989
.989

6

0.58 (0.30-1.15)

.249

6

1.00 (0.83-1.21)

.989

7

0.96 (0.53-1.72)

.884

7

0.99 (0.82-1.20)

.989

8-10

0.68 (0.40-1.17)

.249

8-10

1.01 (0.77-1.33)

.989

Gleason score

Gleason score

PSA

PSA
<10

0.88 (0.51-1.53)

.690

<10

1.04 (0.88-1.22)

.989

10-20

0.69 (0.39-1.23)

.272

10-20

1.00 (0.86-1.17)

.989

>20

0.60 (0.32-1.13)

.249

>20

0.91 (0.77-1.07)

.989

RT strategy

RT strategy
High-dose RT

3.26 (0.60-17.71)

.249

RT alone

1.07 (0.90-1.27)

.989

RT + STADT

0.83 (0.54-1.29)

.465

High-dose RT

1.04 (0.70-1.56)

.989

RT + LTADT

0.55 (0.27-1.13)

.249

RT + STADT

0.97 (0.88-1.07)

.989

RT alone

0.70 (0.42-1.17)

.249

RT + LTADT

0.98 (0.80-1.19)

.989

Race

Race
Black vs White men 0.72 (0.54-0.97)

.032
0.30

0.55

0.75 1

Black vs White men

0.99 (0.92-1.07)

2

.870
0.55

sHR (95% CI)

0.75

1

1.7

sHR (95% CI)

Associations between race and prostate cancer–specific mortality (A) and all-cause
mortality (B) were modeled with the unadjusted Fine-Gray method yielding
subdistribution hazard ratio (sHR) and Cox proportional hazards models yielding hazard
ratios (HRs), respectively. Trial-specific estimates were generated and then combined
with a 2-step meta-analysis method with random effects to obtain overall estimates.

LTADT indicates long-term androgen deprivation therapy; NCCN, National
Comprehensive Cancer Network; PSA, prostate-specific antigen; RT, radiotherapy; sHR,
subdistribution hazard ratio; and STADT, short-term androgen deprivation therapy. SI
conversion of PSA levels to micrograms per liter is 1:1.

Table 2. Multivariable Competing Risk Analysis for Factors Associated With Treatment Outcome
BCR

DM

PCSM

Characteristic

sHR (95% CI)

P value

sHR (95% CI)

P value

sHR (95% CI)

P value

Race (Black vs White)

0.79 (0.72-0.88)

<.001

0.69 (0.55-0.87)

.002

0.68 (0.50-0.93)

.01

RT + STADT vs RT alone

0.63 (0.54-0.73)

<.001

0.64 (0.46-0.88)

.006

0.55 (0.40-0.75)

<.001

RT+ LTADT vs RT alone

0.37 (0.30-0.46)

<.001

0.41 (0.28-0.62)

<.001

0.38 (0.25-0.58)

<.001

High dose RT vs RT alone

0.60 (0.51-0.72)

<.001

0.64 (0.40-1.00)

.05

0.37 (0.15-0.92)

.03

RT+ LTADT vs RT + STADT

0.59 (0.50-0.69)

<.001

0.65 (0.51-0.83)

<.001

0.70 (0.53-0.92)

.01

High dose RT vs RT + STADT

0.96 (0.77-1.20)

.74

1.00 (0.57-1.75)

.10

0.68 (0.26-1.78)

.43

High dose RT vs RT + LTADT

1.64 (1.25-2.15)

<.001

1.55 (0.84-2.84)

.16

0.98 (0.36-2.66)

.97

Age (1-y increase)

0.98 (0.97-0.99)

<.001

0.97 (0.96-0.99)

<.001

0.98 (0.95-1.01)

.18

Ln(iPSA) (1-U increase)

1.60 (1.41-1.80)

<.001

1.36 (1.23-1.51)

<.001

1.80 (1.06-3.04)

.03

T category (1-U increase)

1.12 (1.05-1.20)

.001

1.23 (1.11-1.37)

<.001

1.60 (0.88-2.90)

.12

Gleason score (1-U increase)

1.22 (1.14-1.31)

<.001

1.48 (1.27-1.74)

<.001

1.55 (1.41-1.70)

<.001

Treatment strategy

Abbreviations: BCR, biochemical recurrence; DM, distant metastasis; LTADT, long-term
androgen deprivation therapy; PCSM, prostate cancer-specific mortality; RT,

radiotherapy; STADT, short-term androgen deprivation therapy; sHR, subdistribution
hazard ratio.
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unadjusted competing risks and incidence rates. However, we performed an adjusted network metaanalysis that supported our finding that race appeared to be independently associated with
improved BCR, DM, and PCSM.
These results provide high-level evidence to question the belief that prostate cancer among
Black men necessarily portends a worse prognosis compared with White men. This belief may be a
factor in differences in the approach to cancer therapy, thereby leading to the use of more aggressive
treatments than might be necessary, which carry greater risks of decreasing the quality of life and
distracting attention from other important factors associated with outcome and sources of disparity,
such as access to care.32,33 The findings between race and outcome in our analysis were derived from
patient groups that not only had access to enrollment but were enrolled in randomized clinical trials,
with all patients (Black and White) receiving the same treatment. There is an important distinction
between access to trials and enrollment as Black men have been reported to be notably less willing to
discuss trials than White men owing to medical mistrust.34 In the general population, such equity in
access to care and receipt of treatment are not realized, therefore leading to population-level
disparities in outcome. Engaging Black men and increasing the representation of the Black
population in various cancer prevention and treatment studies is warranted and can be facilitated by
connecting with community stakeholders and identifying study champions.35 Moreover, most death
events in both Black and White men are due to diseases other than prostate cancer, underscoring
the importance of overall health in men with prostate cancer. Nononcologic care is needed, and
disparities in overall health care access and receipt can also be factors associated with survival
outcomes on a population level. However, these results do not suggest that there are no biological
differences that might be associated with differences in prostate cancer incidence between racial
groups. It is possible that the association with differential treatment response might be, at least in
part, explained by differences in underlying biologic factors. Studies have reported distinct
characteristics of prostate cancer in Black and White men at the genetic,36-38 epigenetic,39 and
immunological level.40 These differences may have contributed to improved efficacy of multiple
lines of systemic therapy in Black men compared with non-Black men with locally advanced or
metastatic disease.10

Limitations
This study has limitations. First, none of the trials included in this analysis was designed to investigate
associations between race and outcome of the trial intervention. Therefore, these comparisons are
post hoc and susceptible to residual confounding beyond what would be expected for optimal
prespecified subgroup analyses.41 Second, race was defined on the basis of self-identification and is
a sociopolitical construct that may not intrinsically capture biologic factors.42 Ancestry may be a
more appropriate metric for capturing biological phenomena and increasing our understanding of
health disparities, but has not been historically abstracted for clinical trials. Third, salvage therapies
after BCR or DM were not standardized, potentially leading to secondary confounding of the end
points of PCSM and ACM. We addressed this limitation by including these earlier outcomes as end
points of interest as well, but it is also possible that intervention after the development of BCR might
have had a differential effect on the incidence of DM. Fourth, data for other prognostic variables,
such as comorbidity, socioeconomic status, and performance status, were not uniformly available
and could not be adjusted for. It is possible that a lack of such information and the inability to adjust
thereof precluded us from detecting a significant difference in ACM. Given the known barriers toward
enrolling individuals of minority racial and ethnic groups in clinical trials,43 the external validity of our
results may be different for Black and White men.

Conclusions
In this meta-analysis, Black men enrolled in randomized clinical trials with long-term follow-up
appeared to have higher risk disease features at the time of trial enrollment, but nonetheless had
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better BCR, DM, and PCSM outcomes with RT-based therapy compared with White men. The findings
suggest that Black race may be an independent favorable prognostic variable.
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